Molecular Signatures of Cutaneous Dupilumab Response

Description

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Conditions

Atopic Dermatitis

Talk to us

Study Overview

On this page

Study Details

Study overview

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Molecular Signatures of Cutaneous Dupilumab Response

Molecular Signatures of Cutaneous Dupilumab Response

Condition
Atopic Dermatitis
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. 18 years of age or older
  • 2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7
  • 1. Known pregnancy
  • 2. Known immunodeficiencies
  • 3. Known parasitic infection -

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Jeffrey Cheng, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Raymond Cho, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2026-02-01